{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus+capsule&page=2", "query": { "intervention": "Tacrolimus capsule", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus+capsule&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T16:29:32.038Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00938860", "title": "Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C", "Liver Transplantation" ], "interventions": [ { "name": "cyclosporin (Neoral)", "type": "DRUG" }, { "name": "tacrolimus (Prograf)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 92, "start_date": "2009-09", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-05-22", "last_synced_at": "2026-09-27T16:29:32.038Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Palo Alto, California • San Francisco, California + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00938860" }, { "nct_id": "NCT01256294", "title": "Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Transplant" ], "interventions": [ { "name": "Generic Tacrolimus", "type": "DRUG" }, { "name": "Branded Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2010-10", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2012-06-21", "last_synced_at": "2026-09-27T16:29:32.038Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01256294" }, { "nct_id": "NCT00608244", "title": "Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Failure" ], "interventions": [ { "name": "LCP Tacro", "type": "DRUG" }, { "name": "Prograf", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veloxis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 59, "start_date": "2007-11", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2015-08-28", "last_synced_at": "2026-09-27T16:29:32.038Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00608244" }, { "nct_id": "NCT05707377", "title": "A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Primary Membranous Nephropathy" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 178, "start_date": "2023-04-17", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-27T16:29:32.038Z", "location_count": 4, "location_summary": "Granada Hills, California • Palo Alto, California • Minneapolis, Minnesota + 1 more", "locations": [ { "city": "Granada Hills", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05707377" }, { "nct_id": "NCT00787761", "title": "Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Disorders", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic HSCT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 24, "start_date": "2007-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2012-10-01", "last_synced_at": "2026-09-27T16:29:32.038Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787761" }, { "nct_id": "NCT02588339", "title": "Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease", "GVHD" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2016-03-04", "completion_date": "2021-07-13", "has_results": true, "last_update_posted_date": "2021-07-21", "last_synced_at": "2026-09-27T16:29:32.038Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02588339" }, { "nct_id": "NCT00817206", "title": "Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Failure" ], "interventions": [ { "name": "LCP-Tacro", "type": "DRUG" }, { "name": "Prograf", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veloxis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 326, "start_date": "2008-12", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2015-09-10", "last_synced_at": "2026-09-27T16:29:32.038Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00817206" }, { "nct_id": "NCT02118896", "title": "Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Transplantation", "Liver Transplantation", "Kidney Transplantation" ], "interventions": [ { "name": "FK506E", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Europe Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 850, "start_date": "2003-02-24", "completion_date": "2009-10-07", "has_results": true, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-09-27T16:29:32.038Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02118896" }, { "nct_id": "NCT00587158", "title": "Oral Paricalcitol in Kidney Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Transplant; Failure, Kidney", "Renal Disease, End Stage", "Hyperparathyroidism, Secondary" ], "interventions": [ { "name": "Paricalcitol", "type": "DRUG" }, { "name": "Corticosteroid Avoidance Immune Suppression Protocol", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2007-01", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2013-05-13", "last_synced_at": "2026-09-27T16:29:32.038Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00587158" }, { "nct_id": "NCT06120140", "title": "Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Amivantamab IV", "type": "DRUG" }, { "name": "Amivantamab SC", "type": "DRUG" }, { "name": "Lazertinib", "type": "DRUG" }, { "name": "Doxycycline", "type": "DRUG" }, { "name": "Minocycline", "type": "DRUG" }, { "name": "Clindamycin", "type": "DRUG" }, { "name": "Chlorhexidine", "type": "DRUG" }, { "name": "Noncomedogenic skin moisturizer", "type": "OTHER" }, { "name": "Ruxolitinib", "type": "OTHER" }, { "name": "Tacrolimus", "type": "OTHER" }, { "name": "Zinc gluconate", "type": "DRUG" }, { "name": "Propranolol", "type": "DRUG" }, { "name": "Timolol", "type": "DRUG" }, { "name": "Clobetasol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 305, "start_date": "2024-02-16", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-09-27T16:29:32.038Z", "location_count": 28, "location_summary": "Chandler, Arizona • Duarte, California • Fullerton, California + 25 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06120140" } ] }